Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report

Jiaxin Wang; Yu Ding; Yuhong Lu; Jiaxiong Tan

doi:doi:10.11648/j.jctr.20200803.12

| Peer-Reviewed

Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report

Jiaxin Wang, Yu Ding, Yuhong Lu, Jiaxiong Tan

Published in Journal of Cancer Treatment and Research (Volume 8, Issue 3)

Received: 5 August 2020 Accepted: 27 August 2020 Published: 10 September 2020

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Primary lymphoma of prostate is rare representing approximately 0.1% of all non-Hogdk in lymphomas. This type of lymphoma is more common in men with an average age of 60 years old. Dysuria is the most common symptom of prostatic lymphoma, which can lead to misdiagnosis of benign prostatic hyperplasia and adenocarcinoma easily. Besides, PSA was widely considered in the normal range in most patients with prostatic lymphoma, only a few patients showed elevated. We report a case of a 72-year-old primary prostatic diffuse large B-cell lymphoma patient with a significant increasing of PSA, developed Central Nervous System (CNS) symptoms after completing a cycle of R-CHOP therapy. Unfortunately, the patients received R-CHP in combination with high dose immunoglobulin, after a brief relief of CNS symptoms, the similar CNS symptoms returning again later. Involvement of CNS symptoms during therapy represents a serious complication of aggressive lymphoma, which is rare occurring nearly 5% of non-Hodgkin lymphoma and is considered as a high-risk model In conclusions, primary prostatic lymphoma with an increasing of prostatic-specific antigen is a rare case that is easily misdiagnosed. R-CHOP is till the recommended regimen, but other safe and effective alternatives are urgently needed when obvious CNS symptoms occurred during treatment.

Published in	Journal of Cancer Treatment and Research (Volume 8, Issue 3)
DOI	10.11648/j.jctr.20200803.12
Page(s)	60-63
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2020. Published by Science Publishing Group

Keywords

Lymphoma, Prostate, Chemotherapy, Central Nervous System Symptoms

References

[1]	Kumar P, Rahman K, Hussein N, Gupta R, Nityanand S. Primary prostatic non-Hodgkin's lymphoma presenting with features of prostatism. J Cancer Res Ther. 2019; 15 (Supplement): S178-S179.
[2]	Sivaraman A, Rao N, Choubhey S, Adhyam M. Primary prostatic lymphoma in a young male with hiv infection. Indian J Surg Oncol. 2014; 5 (3): 184-185.
[3]	Rao RN, Bansal M, Raghuvanshi S, Ansari MS, Neyaz Z. Diffuse large B-cell non-Hodgkin lymphoma of the prostate presenting with urinary outlet obstruction: A case report. Urol Ann. 2015; 7 (1): 100-103.
[4]	Manabe M, Hayashi Y, Yoshii Y, Mukai S, Sakamoto E, Kanashima H, et al. Primary diffuse large B-Cell lymphoma of the prostate presenting with urinary retention and dyschezia for which rituximab-combined CHOP therapy was effective-a case presentation. Gan To Kagaku Ryoho. 2012; 39 (11): 1733-1735.
[5]	Steuter J, Weisenburger DD, Bociek RG, Bierman P, Vose J, Bast M, et al. Non-Hodgkin lymphoma of the prostate. Am J Hematol. 2011; 86 (11): 952-954.
[6]	Bostwick DG, Mann RB. Malignant lymphomas involving the prostate. A study of 13 cases. Cancer. 1985; 56 (12): 2932-2938.
[7]	Petkovic I, Stojnev S, Krstic M, Pejcic I, Vrbic S. Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? Vojnosanit Pregl. 2016; 73 (11): 1072-1075.
[8]	Essadi I, Ismaili N, Tazi E, Elmajjaoui S, Saidi A, Ichou M, et al. Primary lymphoma of the head and neck: two case reports and review of the literature. Cases J. 2008; 1 (1): 426.
[9]	Buckstein R, Lim W, Franssen E, Imrie KL. CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leuk Lymphoma. 2003; 44 (6): 955-962.
[10]	Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, et al. Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis. J Hematol Oncol. 2020; 13 (1): 1.
[11]	Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377 (26): 2531-2544.
[12]	Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, et al. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. N Engl J Med. 2017; 377 (8): 783-784.
[13]	Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgk Figure 2. Immunohistochemical characterization of the prostate biopsy sample. A:HE, x400; B: CD20 (+), x400; C:CD79a (+), x400; D:PAX-5 (+), x400; E: CD3 (+), x400; F: CD10 (+), x400; G:MUM1 (+), X400; H:bcl-6 (+), x400. in lymphoma than DLBCL. Blood. 2018; 131 (16): 1809-1819.

Cite This Article

Plain Text BibTeX RIS

APA Style

Jiaxin Wang, Yu Ding, Yuhong Lu, Jiaxiong Tan. (2020). Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report. Journal of Cancer Treatment and Research, 8(3), 60-63. https://doi.org/10.11648/j.jctr.20200803.12

Copy | Download

ACS Style

Jiaxin Wang; Yu Ding; Yuhong Lu; Jiaxiong Tan. Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report. J. Cancer Treat. Res. 2020, 8(3), 60-63. doi: 10.11648/j.jctr.20200803.12

Copy | Download

AMA Style

Jiaxin Wang, Yu Ding, Yuhong Lu, Jiaxiong Tan. Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report. J Cancer Treat Res. 2020;8(3):60-63. doi: 10.11648/j.jctr.20200803.12

Copy | Download

@article{10.11648/j.jctr.20200803.12,
  author = {Jiaxin Wang and Yu Ding and Yuhong Lu and Jiaxiong Tan},
  title = {Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report},
  journal = {Journal of Cancer Treatment and Research},
  volume = {8},
  number = {3},
  pages = {60-63},
  doi = {10.11648/j.jctr.20200803.12},
  url = {https://doi.org/10.11648/j.jctr.20200803.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20200803.12},
  abstract = {Primary lymphoma of prostate is rare representing approximately 0.1% of all non-Hogdk in lymphomas. This type of lymphoma is more common in men with an average age of 60 years old. Dysuria is the most common symptom of prostatic lymphoma, which can lead to misdiagnosis of benign prostatic hyperplasia and adenocarcinoma easily. Besides, PSA was widely considered in the normal range in most patients with prostatic lymphoma, only a few patients showed elevated. We report a case of a 72-year-old primary prostatic diffuse large B-cell lymphoma patient with a significant increasing of PSA, developed Central Nervous System (CNS) symptoms after completing a cycle of R-CHOP therapy. Unfortunately, the patients received R-CHP in combination with high dose immunoglobulin, after a brief relief of CNS symptoms, the similar CNS symptoms returning again later. Involvement of CNS symptoms during therapy represents a serious complication of aggressive lymphoma, which is rare occurring nearly 5% of non-Hodgkin lymphoma and is considered as a high-risk model In conclusions, primary prostatic lymphoma with an increasing of prostatic-specific antigen is a rare case that is easily misdiagnosed. R-CHOP is till the recommended regimen, but other safe and effective alternatives are urgently needed when obvious CNS symptoms occurred during treatment.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report
AU  - Jiaxin Wang
AU  - Yu Ding
AU  - Yuhong Lu
AU  - Jiaxiong Tan
Y1  - 2020/09/10
PY  - 2020
N1  - https://doi.org/10.11648/j.jctr.20200803.12
DO  - 10.11648/j.jctr.20200803.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 60
EP  - 63
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20200803.12
AB  - Primary lymphoma of prostate is rare representing approximately 0.1% of all non-Hogdk in lymphomas. This type of lymphoma is more common in men with an average age of 60 years old. Dysuria is the most common symptom of prostatic lymphoma, which can lead to misdiagnosis of benign prostatic hyperplasia and adenocarcinoma easily. Besides, PSA was widely considered in the normal range in most patients with prostatic lymphoma, only a few patients showed elevated. We report a case of a 72-year-old primary prostatic diffuse large B-cell lymphoma patient with a significant increasing of PSA, developed Central Nervous System (CNS) symptoms after completing a cycle of R-CHOP therapy. Unfortunately, the patients received R-CHP in combination with high dose immunoglobulin, after a brief relief of CNS symptoms, the similar CNS symptoms returning again later. Involvement of CNS symptoms during therapy represents a serious complication of aggressive lymphoma, which is rare occurring nearly 5% of non-Hodgkin lymphoma and is considered as a high-risk model In conclusions, primary prostatic lymphoma with an increasing of prostatic-specific antigen is a rare case that is easily misdiagnosed. R-CHOP is till the recommended regimen, but other safe and effective alternatives are urgently needed when obvious CNS symptoms occurred during treatment.
VL  - 8
IS  - 3
ER  -

Copy | Download

Author Information

Jiaxin Wang

Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Yu Ding

Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Yuhong Lu

Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China
Jiaxiong Tan

Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Jiaxin Wang, Yu Ding, Yuhong Lu, Jiaxiong Tan. (2020). Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report. Journal of Cancer Treatment and Research, 8(3), 60-63. https://doi.org/10.11648/j.jctr.20200803.12

Copy | Download

ACS Style

Jiaxin Wang; Yu Ding; Yuhong Lu; Jiaxiong Tan. Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report. J. Cancer Treat. Res. 2020, 8(3), 60-63. doi: 10.11648/j.jctr.20200803.12

Copy | Download

AMA Style

Jiaxin Wang, Yu Ding, Yuhong Lu, Jiaxiong Tan. Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report. J Cancer Treat Res. 2020;8(3):60-63. doi: 10.11648/j.jctr.20200803.12

Copy | Download

@article{10.11648/j.jctr.20200803.12,
  author = {Jiaxin Wang and Yu Ding and Yuhong Lu and Jiaxiong Tan},
  title = {Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report},
  journal = {Journal of Cancer Treatment and Research},
  volume = {8},
  number = {3},
  pages = {60-63},
  doi = {10.11648/j.jctr.20200803.12},
  url = {https://doi.org/10.11648/j.jctr.20200803.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20200803.12},
  abstract = {Primary lymphoma of prostate is rare representing approximately 0.1% of all non-Hogdk in lymphomas. This type of lymphoma is more common in men with an average age of 60 years old. Dysuria is the most common symptom of prostatic lymphoma, which can lead to misdiagnosis of benign prostatic hyperplasia and adenocarcinoma easily. Besides, PSA was widely considered in the normal range in most patients with prostatic lymphoma, only a few patients showed elevated. We report a case of a 72-year-old primary prostatic diffuse large B-cell lymphoma patient with a significant increasing of PSA, developed Central Nervous System (CNS) symptoms after completing a cycle of R-CHOP therapy. Unfortunately, the patients received R-CHP in combination with high dose immunoglobulin, after a brief relief of CNS symptoms, the similar CNS symptoms returning again later. Involvement of CNS symptoms during therapy represents a serious complication of aggressive lymphoma, which is rare occurring nearly 5% of non-Hodgkin lymphoma and is considered as a high-risk model In conclusions, primary prostatic lymphoma with an increasing of prostatic-specific antigen is a rare case that is easily misdiagnosed. R-CHOP is till the recommended regimen, but other safe and effective alternatives are urgently needed when obvious CNS symptoms occurred during treatment.},
 year = {2020}
}

Copy | Download

TY  - JOUR
T1  - Primary Prostatic Lymphoma Presenting with Features of Prostatism Developed Central Nervous System (CNS) Symptoms During Chemotherapy: A Case Report
AU  - Jiaxin Wang
AU  - Yu Ding
AU  - Yuhong Lu
AU  - Jiaxiong Tan
Y1  - 2020/09/10
PY  - 2020
N1  - https://doi.org/10.11648/j.jctr.20200803.12
DO  - 10.11648/j.jctr.20200803.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 60
EP  - 63
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20200803.12
AB  - Primary lymphoma of prostate is rare representing approximately 0.1% of all non-Hogdk in lymphomas. This type of lymphoma is more common in men with an average age of 60 years old. Dysuria is the most common symptom of prostatic lymphoma, which can lead to misdiagnosis of benign prostatic hyperplasia and adenocarcinoma easily. Besides, PSA was widely considered in the normal range in most patients with prostatic lymphoma, only a few patients showed elevated. We report a case of a 72-year-old primary prostatic diffuse large B-cell lymphoma patient with a significant increasing of PSA, developed Central Nervous System (CNS) symptoms after completing a cycle of R-CHOP therapy. Unfortunately, the patients received R-CHP in combination with high dose immunoglobulin, after a brief relief of CNS symptoms, the similar CNS symptoms returning again later. Involvement of CNS symptoms during therapy represents a serious complication of aggressive lymphoma, which is rare occurring nearly 5% of non-Hodgkin lymphoma and is considered as a high-risk model In conclusions, primary prostatic lymphoma with an increasing of prostatic-specific antigen is a rare case that is easily misdiagnosed. R-CHOP is till the recommended regimen, but other safe and effective alternatives are urgently needed when obvious CNS symptoms occurred during treatment.
VL  - 8
IS  - 3
ER  -

Copy | Download